Ideas

Molecular therapy for Non-alcoholic fatty liver disease (NAFLD): Victoza/Saxenda, an anti-hyperglycemic drug, promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 12/November/2017, 11.15 pm
Molecular therapy for Non-alcoholic fatty liver disease (NAFLD): Victoza/Saxenda, an anti-hyperglycemic drug, promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 12/November/2017, 11.15 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Significance of the study: Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in…

read more

Life-extension therapy: Mangiferin, isolated from Mangifera Indica, inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span, 12/November/2017, 11.10 pm
Life-extension therapy: Mangiferin, isolated from Mangifera Indica, inhibits the expression of Ribosomal protein S6 kinase 1 (p70S6 Kinase) and extends mammalian life span, 12/November/2017, 11.10 pm 960 720 Dr Boomi's Genom-2-Discovery Center

What they say: A study from the Institute of Healthy Ageing, Centre for Diabetes and Endocrinology, Department of Medicine, University College London, London WC1E 6JJ, UK shows that “Ribosomal protein S6 kinase 1…

read more

Natural product therapy for pulmonary arterial hypertension:Mangiferin, isolated from Mangifera Indica, inhibits the development of pulmonary arterial hypertension via down regulation of  Notch3 and its target gene Hes5, 11/November/2017, 11.59 pm
Natural product therapy for pulmonary arterial hypertension:Mangiferin, isolated from Mangifera Indica, inhibits the development of pulmonary arterial hypertension via down regulation of  Notch3 and its target gene Hes5, 11/November/2017, 11.59 pm 960 720 Dr Boomi's Genom-2-Discovery Center

What they say:  A study from the University of California, La Jolla, California, USA shows that “Notch3 signaling promotes the development of pulmonary arterial hypertension.” This study was published in the 15 November  2009 issue of the journal “Nature Medicine”[the number 1 journal in General…

read more

Vitamin-based regenerative therapy for reversing diabetes: Vitamin-C increases the expression of Sox17, Sox2, Pdx-1, and Ngn3, decreases mTOR expression, promotes regeneration of insulin-producing ß cells, increases insulin secretion, promotes glucose homeostasis and reverses T1D and T2D via down regulation of its target gene, 11/November/2017, 11.54 pm
Vitamin-based regenerative therapy for reversing diabetes: Vitamin-C increases the expression of Sox17, Sox2, Pdx-1, and Ngn3, decreases mTOR expression, promotes regeneration of insulin-producing ß cells, increases insulin secretion, promotes glucose homeostasis and reverses T1D and T2D via down regulation of its target gene, 11/November/2017, 11.54 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A study from the Longevity Institute, School of Gerontology, Department of Biological Sciences, University of Southern California, 3715 McClintock Avenue, Los Angeles, California, USA; and Koch Institute…

read more

Natural product therapy for Non-alcoholic fatty liver disease (NAFLD): Mangiferin, isolated from Mangifera Indica, promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 11/November/2017, 11.40 pm
Natural product therapy for Non-alcoholic fatty liver disease (NAFLD): Mangiferin, isolated from Mangifera Indica, promotes degradation of HMGCR, decreases the levels of triglycerides, free cholesterol, and total cholesterol and prevents the progression of Non-alcoholic fatty liver disease (NAFLD via down regulation of its target gene, 11/November/2017, 11.40 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Significance of the study: Given that: (1)  15-30% of Western populations suffer from Non-alcoholic fatty liver disease (NAFLD), while 6-25% of Asian populations suffer from it; (2) 75 to 100 million people in…

read more

Natural product-based therapy for Deafness: A therapeutic mix encompassing  3-O-laurylglyceryl ascorbate (VC-3LG),  Cholecalciferol, Ajoene and DIM (VC-3LGCAD)  increases the expression of ATG5 (Autophagy-related 5), prevents aggregation of proteins in inclusion bodies, inhibits hair cell degeneration,  improves hearing loss via up regulation of its target genes, 11/November/2017, 11.35 pm
Natural product-based therapy for Deafness: A therapeutic mix encompassing  3-O-laurylglyceryl ascorbate (VC-3LG),  Cholecalciferol, Ajoene and DIM (VC-3LGCAD)  increases the expression of ATG5 (Autophagy-related 5), prevents aggregation of proteins in inclusion bodies, inhibits hair cell degeneration,  improves hearing loss via up regulation of its target genes, 11/November/2017, 11.35 pm 960 720 Dr Boomi's Genom-2-Discovery Center

What we say: Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-based therapy for Deafness: A therapeutic mix encompassing  3-O-laurylglyceryl ascorbate (VC-3LG),  Cholecalciferol, Ajoene and DIM (VC-3LGCAD)  increases the expression of…

read more
Start Typing